AR086932A2 - Metodo para la produccion de polipeptidos - Google Patents
Metodo para la produccion de polipeptidosInfo
- Publication number
- AR086932A2 AR086932A2 ARP120102112A AR086932A2 AR 086932 A2 AR086932 A2 AR 086932A2 AR P120102112 A ARP120102112 A AR P120102112A AR 086932 A2 AR086932 A2 AR 086932A2
- Authority
- AR
- Argentina
- Prior art keywords
- accumulated
- culture
- amino acids
- molar ratio
- glutamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee un sistema mejorado para la producción a gran escala de proteínas y Ab en cultivo de células, en particular, en medios caracterizados por una o más de las siguientes características: i) una concentración acumulada de aminoácidos mayor que aproximadamente 70 mM; ii) una relación molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; iii) una relación molar de glutamina acumulada a aminoácidos totales acumulados inferior a aproximadamente 0,2; iv) una relación molar de ión inorgánico acumulado a aminoácidos totales acumulados de entre alrededor de 0,4 y 1; o v) una concentración combinada de glutamina acumulada y asparagina acumulada de entre aproximadamente 16 y 36 mM. El uso de dicho sistema permite altos niveles de producción de Ab, y disminuye la acumulación de ciertos factores indeseables, tales como amonio y lactato. Adicionalmente se proveen métodos de cultivo que incluyen un cambio de temperatura, que habitualmente comprende una disminución en la temperatura cuando el cultivo ha alcanzado alrededor de 20% - 80% de su densidad celular máxima. Alternativa o adicionalmente, la presente provee métodos tales que, después de alcanzar un pico, los niveles de lactato y amonio en el cultivo disminuyen con el transcurso del tiempo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60507404P | 2004-08-27 | 2004-08-27 | |
US60509704P | 2004-08-27 | 2004-08-27 | |
US60494104P | 2004-08-27 | 2004-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086932A2 true AR086932A2 (es) | 2014-01-29 |
Family
ID=35482353
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103594 AR051017A1 (es) | 2004-08-27 | 2005-08-26 | Produccion de polipeptidos |
ARP120102112 AR086932A2 (es) | 2004-08-27 | 2012-06-14 | Metodo para la produccion de polipeptidos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103594 AR051017A1 (es) | 2004-08-27 | 2005-08-26 | Produccion de polipeptidos |
Country Status (20)
Country | Link |
---|---|
US (1) | US7294484B2 (es) |
EP (2) | EP1789571B1 (es) |
JP (1) | JP4864892B2 (es) |
KR (2) | KR20110036780A (es) |
CN (2) | CN102827905B (es) |
AR (2) | AR051017A1 (es) |
AU (1) | AU2005280034B2 (es) |
BR (1) | BRPI0514703A (es) |
CA (1) | CA2578141C (es) |
CR (1) | CR8997A (es) |
EC (1) | ECSP077353A (es) |
EG (1) | EG26462A (es) |
ES (1) | ES2628012T3 (es) |
IL (1) | IL181589A0 (es) |
MX (1) | MX2007002380A (es) |
NO (1) | NO342433B1 (es) |
SG (2) | SG158092A1 (es) |
TW (1) | TWI384069B (es) |
WO (1) | WO2006026445A1 (es) |
ZA (1) | ZA200702483B (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1482031B1 (en) * | 1996-08-30 | 2015-10-28 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
CN101282990B (zh) * | 2005-08-26 | 2013-04-03 | 阿雷斯贸易股份有限公司 | 糖基化干扰素-β的制备方法 |
AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
JP5199112B2 (ja) * | 2005-12-09 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | Fsh又はfsh変異体を精製するための方法 |
CN101360820A (zh) | 2006-01-04 | 2009-02-04 | 巴克斯特国际公司 | 无寡肽的细胞培养基 |
CN101496387B (zh) | 2006-03-06 | 2012-09-05 | 思科技术公司 | 用于移动无线网络中的接入认证的系统和方法 |
AU2007272957B2 (en) * | 2006-07-13 | 2014-05-01 | Wyeth Llc | Production of glycoproteins |
KR20090074040A (ko) | 2006-09-13 | 2009-07-03 | 아보트 러보러터리즈 | 세포 배양의 개선 |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
EP2064315B1 (en) * | 2006-11-03 | 2015-05-13 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
ES2538986T3 (es) * | 2006-11-08 | 2015-06-25 | Wyeth Llc | Medios diseñados racionalmente para un cultivo celular |
EP2924113B1 (en) * | 2007-03-02 | 2019-04-10 | Wyeth LLC | Use of copper and glutamate in cell culture for production of polypeptides |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
KR101574355B1 (ko) | 2007-04-26 | 2015-12-11 | 추가이 세이야쿠 가부시키가이샤 | 고농도 아미노산 함유 배지를 사용한 세포의 배양 방법 |
US20090042253A1 (en) | 2007-08-09 | 2009-02-12 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
US8319819B2 (en) | 2008-03-26 | 2012-11-27 | Cisco Technology, Inc. | Virtual round-table videoconference |
CN107090481A (zh) * | 2008-04-17 | 2017-08-25 | 惠氏有限责任公司 | 提高骨形成蛋白产量的方法 |
KR102018475B1 (ko) | 2008-09-15 | 2019-09-04 | 제넨테크, 인크. | 세포 오스몰농도를 조절하기 위한 조성물 및 방법 |
US8694658B2 (en) | 2008-09-19 | 2014-04-08 | Cisco Technology, Inc. | System and method for enabling communication sessions in a network environment |
SG10201702922VA (en) | 2008-10-20 | 2017-06-29 | Abbvie Inc | Isolation and purification of antibodies using protein a affinity chromatography |
SG10201702951RA (en) | 2008-10-20 | 2017-06-29 | Abbvie Inc | Viral inactivation during purification of antibodies |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
EP3431588A1 (en) | 2009-08-11 | 2019-01-23 | F. Hoffmann-La Roche AG | Production of proteins in glutamine-free cell culture media |
GB0917647D0 (en) * | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
KR20130009744A (ko) * | 2010-01-13 | 2013-01-23 | 에이피티 테라퓨틱스 인코포레이션 | 치료적 아피라제 컨스트럭트, 아피라제 제제 및 제조 방법 |
US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
EP3330370B1 (en) | 2010-04-26 | 2021-02-24 | Novartis AG | Process for cultivation of cho cells |
US9428727B2 (en) * | 2010-04-26 | 2016-08-30 | Novartis Ag | Cell culture medium |
MX2012012525A (es) | 2010-04-26 | 2012-11-23 | Novartis Ag | Medio de cultivo mejorado. |
EP2591094B1 (en) * | 2010-07-08 | 2018-09-05 | Baxalta GmbH | Method of producing recombinant adamts13 in cell culture |
SG187198A1 (en) | 2010-08-05 | 2013-03-28 | Amgen Inc | Dipeptides to enhance yield and viability from cell cultures |
EP2606119A1 (en) | 2010-08-20 | 2013-06-26 | Wyeth LLC | Cell culture of growth factor-free adapted cells |
CN102382794B (zh) * | 2010-09-01 | 2013-09-18 | 山东新时代药业有限公司 | 一种哺乳动物细胞的灌流培养方法 |
US8599865B2 (en) | 2010-10-26 | 2013-12-03 | Cisco Technology, Inc. | System and method for provisioning flows in a mobile network environment |
US9143725B2 (en) | 2010-11-15 | 2015-09-22 | Cisco Technology, Inc. | System and method for providing enhanced graphics in a video environment |
US8730297B2 (en) | 2010-11-15 | 2014-05-20 | Cisco Technology, Inc. | System and method for providing camera functions in a video environment |
US9338394B2 (en) | 2010-11-15 | 2016-05-10 | Cisco Technology, Inc. | System and method for providing enhanced audio in a video environment |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
MY169935A (en) | 2011-04-29 | 2019-06-18 | Biocon Biologics India Ltd | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" |
WO2013006479A2 (en) * | 2011-07-01 | 2013-01-10 | Amgen Inc. | Mammalian cell culture |
US8682087B2 (en) | 2011-12-19 | 2014-03-25 | Cisco Technology, Inc. | System and method for depth-guided image filtering in a video conference environment |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CA2917484A1 (en) * | 2013-07-06 | 2015-01-15 | Cadila Healthcare Limited | Improved process for production of monoclonal antibodies |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US11390663B2 (en) * | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
SI3110961T1 (sl) | 2014-02-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina |
EP3119876A1 (en) | 2014-03-19 | 2017-01-25 | Pfizer Inc. | Method of cell culture |
TWI776235B (zh) * | 2014-06-09 | 2022-09-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
EP3227454B1 (en) | 2014-12-01 | 2020-01-29 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
WO2016196261A1 (en) * | 2015-05-29 | 2016-12-08 | Boehringer Ingelheim International Gmbh | Cell-controlled perfusion in continuous culture |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CA3214798A1 (en) | 2015-09-23 | 2017-03-30 | Pfizer Inc. | Cells and method of cell culture |
CN108473945A (zh) | 2015-11-17 | 2018-08-31 | 辉瑞公司 | 用于在细菌细胞培养物中生产多糖的培养基和发酵方法 |
US20190112572A1 (en) * | 2016-04-05 | 2019-04-18 | Pfizer Inc. | Cell culture process |
DK3372670T3 (da) * | 2017-03-09 | 2019-05-20 | Evonik Technochemie Gmbh | Dyrkningsmedier, der omfatter n-acyl-x-glutamindipeptider |
WO2019083256A2 (ko) | 2017-10-23 | 2019-05-02 | 주식회사 프로젠 | 변형된 egf 단백질, 이의 생산 방법 및 용도 |
KR102190790B1 (ko) * | 2018-10-19 | 2020-12-15 | 주식회사 프로젠 | 변형된 egf 단백질의 생산 방법 |
JP7471220B2 (ja) * | 2017-11-30 | 2024-04-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 哺乳動物細胞の培養方法 |
US11634499B2 (en) | 2018-11-13 | 2023-04-25 | Janssen Biotech, Inc. | Control of trace metals during production of anti-CD38 antibodies |
EP3891292A1 (en) | 2018-12-06 | 2021-10-13 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
CN113025648B (zh) * | 2019-12-09 | 2023-06-02 | 广东菲鹏制药股份有限公司 | Expi293细胞瞬时表达目标蛋白的方法及其应用 |
JP2023542820A (ja) | 2020-08-31 | 2023-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略 |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ph建模及控制之系統及方法 |
WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
WO2023167852A2 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Cell culture methods for antibody production |
US20240010709A1 (en) | 2022-05-25 | 2024-01-11 | Genentech, Inc. | Methods for preparing mammalian cells for perfusion cell culture |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
EP0494955B1 (en) | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5156964A (en) | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
GB9118664D0 (en) | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
DE4313620A1 (de) * | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamsterzellinien und Verfahren zur Glykoproteingewinnung |
JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片 |
US6310185B1 (en) | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US20020012991A1 (en) * | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
DE60229051D1 (de) | 2001-04-30 | 2008-11-06 | Lilly Co Eli | Humanisierte antikörper |
US7318923B2 (en) | 2001-04-30 | 2008-01-15 | Eli Lilly And Company | Humanized anti-βantibodies |
US20030087372A1 (en) | 2001-06-13 | 2003-05-08 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7572763B2 (en) | 2002-02-21 | 2009-08-11 | Wyeth | Follistatin domain containing proteins |
BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
SG187991A1 (en) | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
-
2005
- 2005-08-25 TW TW94129070A patent/TWI384069B/zh not_active IP Right Cessation
- 2005-08-25 US US11/213,308 patent/US7294484B2/en active Active
- 2005-08-26 CN CN201210189727.XA patent/CN102827905B/zh not_active Expired - Fee Related
- 2005-08-26 EP EP05792494.6A patent/EP1789571B1/en not_active Revoked
- 2005-08-26 SG SG200907913-8A patent/SG158092A1/en unknown
- 2005-08-26 MX MX2007002380A patent/MX2007002380A/es active IP Right Grant
- 2005-08-26 AU AU2005280034A patent/AU2005280034B2/en active Active
- 2005-08-26 CA CA 2578141 patent/CA2578141C/en active Active
- 2005-08-26 KR KR1020117006936A patent/KR20110036780A/ko not_active Application Discontinuation
- 2005-08-26 BR BRPI0514703-4A patent/BRPI0514703A/pt not_active Application Discontinuation
- 2005-08-26 AR ARP050103594 patent/AR051017A1/es not_active Application Discontinuation
- 2005-08-26 SG SG2013041199A patent/SG190674A1/en unknown
- 2005-08-26 WO PCT/US2005/030437 patent/WO2006026445A1/en active Application Filing
- 2005-08-26 KR KR1020077004807A patent/KR101158447B1/ko active IP Right Grant
- 2005-08-26 JP JP2007530166A patent/JP4864892B2/ja active Active
- 2005-08-26 CN CN2005800368991A patent/CN101048511B/zh not_active Expired - Fee Related
- 2005-08-26 EP EP11156236.9A patent/EP2357250B1/en not_active Revoked
- 2005-08-26 ES ES05792494T patent/ES2628012T3/es active Active
-
2007
- 2007-02-27 IL IL181589A patent/IL181589A0/en unknown
- 2007-02-27 EG EGNA2007000223 patent/EG26462A/en active
- 2007-03-16 CR CR8997A patent/CR8997A/es unknown
- 2007-03-26 ZA ZA2007/02483A patent/ZA200702483B/en unknown
- 2007-03-26 NO NO20071572A patent/NO342433B1/no not_active IP Right Cessation
- 2007-03-27 EC ECSP077353 patent/ECSP077353A/es unknown
-
2012
- 2012-06-14 AR ARP120102112 patent/AR086932A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086932A2 (es) | Metodo para la produccion de polipeptidos | |
ECSP077351A (es) | PRODUCCIÓN DE a-BETA | |
ECSP077354A (es) | PRODUCCIÓN DE TNFR-Ig | |
CL2011002816A1 (es) | Metodo y aparato para reducir una materia prima solida que comprende disponer dicha materia prima sobre elementos con superficies catodicas de un conjunto de celdas bipolares dentro de un alojamiento, hacer circular sal fundida para que entre en contacto con los elementos y la materia prima y aplicar un potencial electrico. | |
AR123811A2 (es) | Composiciones de células madre mesenquimáticas purificadas y métodos relacionados | |
AR061976A1 (es) | Produccion de glicoproteinas | |
CU20120006A7 (es) | Producción de títulos elevados de poliovirus para la producción de vacunas | |
DE602008006086D1 (de) | Zellenneuauswahl in einem drahtlosen kommunikationssystem | |
AR066239A1 (es) | Metodo para la produccion de proteinas mediante celulas cultivadas | |
EA202090067A2 (ru) | Способ получения рекомбинантного adamts13 в культуре клеток | |
AR090822A1 (es) | Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos | |
ATE342958T1 (de) | Verbessertes rollflaschesystem zur kultivierung von zellen und gewebe | |
AR069956A1 (es) | Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas | |
DK1851815T3 (da) | Fremgangsmåde til fremstilling af en brændselscellekatode | |
BR112017018257A2 (pt) | método de fermentação mixotrópica para produzir acetona, isopropanol, ácido butírico e outros bioprodutos, e misturas dos mesmos | |
WO2009155041A3 (en) | Method to modulate hematopoietic stem cell growth | |
DK1495112T3 (da) | Cellekulturmedium | |
CO6390009A2 (es) | Reactor electrobioquimico | |
BRPI0914805B8 (pt) | método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição | |
ATE366803T1 (de) | Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit | |
EA200600772A1 (ru) | Flp-опосредованная рекомбинация | |
BRPI0517942A (pt) | meio de cultura de células isento de soro para células de mamìferos | |
Wenjuan | Effects of Adult Children′ s Migration on Their Financial Support to Old Parents | |
BR112022024866A2 (pt) | Cultura 3d de células precursoras da linhagem mesenquimal ou células-tronco | |
BR112015022580A2 (pt) | métodos para reduzir a concentração de íons amônio e a influência de acúmulo de íons amônio em uma cultura, métodos para manter ou aumentar a produtividade celular e o crescimento celular em uma cultura, e, meio de cultura celular |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |